Exicure gets Nasdaq extension. Nasdaq sets a USD 2.50 million test for Exicure stock

Published on 10/18/2026 at 12:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nasdaq gave Exicure until December 2, 2026 to restore equity compliance. Exicure stock had a USD 1.12 million second-quarter loss.

Compliance and financial pressure

Nasdaq granted Exicure an extension on September 10, 2026, with compliance due December 2, 2026.
Exicure posted a USD 1.12 million net loss in the second quarter of 2026.
Market capitalization was USD 7.3 million on October 16, 2026.

XCUR, US30205M3097, Illustration mit AI erstellt.

Exicure (ISIN US30205M3097) must restore at least USD 2.50 million in stockholders' equity by December 2, 2026, after Nasdaq granted the company an extension. MyChesCo reported that the Nasdaq Listing Qualifications Department granted the extension in a September 10, 2026 letter.

Three compliance dates define the story

Exicure's listing risk developed in stages. On June 5, 2026, Nasdaq notified the company that stockholders' equity had fallen below the USD 2.50 million minimum required under Listing Rule 5550(b)(1), according to MyChesCo. On August 14, 2026, Exicure reported a USD 1.12 million net loss for the second quarter, compared with a USD 1.83 million loss in the first quarter, according to TradingView. Nasdaq's September 10 decision then moved the compliance deadline to December 2, 2026.

What does the equity test mean?

The extension buys time, but it does not restore compliance by itself. Exicure said it would pursue compliance initiatives, while MyChesCo reported that Nasdaq would continue monitoring the company through its next periodic report. A failure to satisfy the requirement could lead to a delisting determination, although Exicure would have appeal rights.

Financial pressure stays visible

The second-quarter loss narrowed by USD 0.71 million from the first quarter, a 38.80 percent improvement in the reported net loss, but the company still had no reported revenue for either period. The finance profile describes Exicure as a biotechnology company with one full-time employee and says it does not have significant operations. Its historic focus was nucleic acid therapies, while its current business includes a co-development agreement involving Burixafor.

Dates investors can measure

The next compliance milestone is December 2, 2026. TradingView lists November 12, 2026 as the next earnings date, creating a potential reporting checkpoint before the Nasdaq deadline.

Small valuation leaves little room

On Nasdaq, XCUR was last quoted at USD 1.12 on October 16, 2026 at 4:00 p.m. ET. Its market capitalization was USD 7.3 million, while the 52-week range stood at USD 0.94 to USD 9.48 on that date. Those figures put the USD 2.50 million equity requirement at roughly one-third of the company's market value.

The further course of trading is shown by the continuously updated real-time quote of Exicure stock.